Russia’s Medme invests in Italian connected healthcare startup

Torino-based startup Biotechware has just secured €2 million euros from MEDME Group, a Russian digital health investor targeting Western Europe.

Biotechware develops hardware and software solutions to collect and transfer clinical information coming from different sources without altering the information. One of these solutions has been designed to collect and process remotely electrocardiographic (ECG) monitoring and blood pressure monitoring tests. It combines a proprietary ECG Holter device with a cloud platform that stores and processes patients’ data.

The Biotechware platform can record, store, analyze and share in real time information related to patients’ health whatever connected medical device and health professional this information may come from.

The funding will cover the startup’s marketing and sales development needs in Italy and help it new markets in Europe, the United States and Asia.

Biotechware previously raised some €1.6 million in total from individual investors as well as from the innovation business incubator of the Torino Polytechnic University (I3P).

MEDME Group defines itself as a “strategic digital health investor” which targets startups “in the junction of IT and medicine, helping them scale up into large multinational companies.”

Founded in 2015, the group is backed by Valentin Doronichev, a business angel with a strong track record in biomedicine. It has invested so far “several millions of USD” in two Russian startups – the digital pathology service UNIM and the health management provider GetDoctor – MEDME Group’s press service told East-West Digital News.

But Medme now focuses on EU startups “with further plans to expand in the US and Asia.” It is in talks with several potential investment targets in the fields of teleradiology and mental health monitoring.

Topics: Biomedicine, Digital services & Apps, E-health, Enterprise software, Finance, International, News, Software, Startups, Venture / Private equity
Scroll to Top

This site is under maintenance. Sorry for the inconvenience.

This site is under maintenance. Sorry for the inconvenience.